iPS cell therapy for Parkinson's disease.
The aim of stem cell therapy for Parkinson's disease (PD) is to reconstruct local synapse formation and/or induce the release of dopamine and cytokines from grafted cells in the putamen. Fetal ventral-midbrain cells reportedly relieve the neurological symptoms of PD patients. However, induced pluripotent stem cells (iPSCs) are expected to provide an alternative donor cell population because of their capacity for self-renewal and pluripotency. A protocol to generate dopaminergic (DA) neurons from iPSCs has been developed, and human ESCs were proven to function in the brains of rat and monkey PD models. We have developed a method of isolating DA neuron progenitors as a donor cell population, which allows safe and efficient transplantation.
Center for iPS Cell Reserach and Application, Kyoto University.
Jun
J
Takahashi
D000818:Animals; D002454:Cell Differentiation; D006801:Humans; D057026:Induced Pluripotent Stem Cells / Q000166:cytology / Q000637:transplantation*; D010300:Parkinson Disease / Q000628:therapy*; D012307:Risk Factors; D014182:Transplantation, Autologous; D014183:Transplantation, Heterologous